Invesco Ltd. Purchases 27,341 Shares of REGENXBIO Inc. $RGNX

Invesco Ltd. boosted its stake in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 52.4% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 79,469 shares of the biotechnology company’s stock after acquiring an additional 27,341 shares during the period. Invesco Ltd. owned 0.16% of REGENXBIO worth $568,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of RGNX. Millennium Management LLC raised its position in REGENXBIO by 406.3% in the fourth quarter. Millennium Management LLC now owns 1,322,344 shares of the biotechnology company’s stock valued at $10,222,000 after purchasing an additional 1,061,187 shares during the last quarter. Vanguard Group Inc. boosted its holdings in REGENXBIO by 16.3% in the first quarter. Vanguard Group Inc. now owns 3,472,988 shares of the biotechnology company’s stock worth $24,832,000 after acquiring an additional 487,036 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of REGENXBIO in the fourth quarter valued at approximately $2,793,000. Two Sigma Investments LP lifted its holdings in shares of REGENXBIO by 209.2% in the fourth quarter. Two Sigma Investments LP now owns 389,428 shares of the biotechnology company’s stock valued at $3,010,000 after purchasing an additional 263,495 shares in the last quarter. Finally, Jane Street Group LLC increased its position in shares of REGENXBIO by 325.3% during the fourth quarter. Jane Street Group LLC now owns 164,911 shares of the biotechnology company’s stock valued at $1,275,000 after acquiring an additional 126,135 shares during the last quarter. Institutional investors own 88.08% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Chardan Capital reissued a “buy” rating and issued a $52.00 target price on shares of REGENXBIO in a research report on Friday, August 8th. Wall Street Zen lowered REGENXBIO from a “hold” rating to a “strong sell” rating in a research note on Saturday, August 9th. Barclays dropped their price target on REGENXBIO from $50.00 to $37.00 and set an “overweight” rating for the company in a research note on Friday, August 8th. HC Wainwright reaffirmed a “buy” rating and set a $34.00 price target on shares of REGENXBIO in a research report on Tuesday, August 19th. Finally, Royal Bank Of Canada reduced their target price on REGENXBIO from $21.00 to $17.00 and set an “outperform” rating on the stock in a report on Friday, August 8th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $28.38.

REGENXBIO Price Performance

NASDAQ RGNX opened at $9.42 on Friday. The business’s fifty day moving average price is $8.63 and its 200-day moving average price is $8.16. The stock has a market capitalization of $475.80 million, a price-to-earnings ratio of -2.74 and a beta of 1.17. REGENXBIO Inc. has a 1-year low of $5.03 and a 1-year high of $13.48.

REGENXBIO (NASDAQ:RGNX) last released its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($1.13) by ($0.25). The firm had revenue of $21.36 million for the quarter, compared to the consensus estimate of $40.87 million. REGENXBIO had a negative net margin of 112.70% and a negative return on equity of 66.95%. Equities research analysts anticipate that REGENXBIO Inc. will post -4.84 EPS for the current year.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.